Cullinan Oncology receives FDA clearance for CLN-619 Phase 1 trial in relapsed/refractory multiple myeloma.
Cullinan Oncology receives FDA clearance for IND application of CLN-619, a potential first-in-class humanized IgG1 monoclonal antibody targeting stress-induced ligands MICA and MICB. The company will initiate a Phase 1 dose-escalation and dose-expansion trial for CLN-619 in treating relapsed/refractory multiple myeloma. CLN-619 aims to restore MICA/B expression on tumor cells, enabling immune recognition and potentially combining with multiple standard therapies for multiple myeloma.
March 01, 2024
5 Articles